NCT04551339 (ZnCOVID-19) is a NA clinical trial of PreserVision AREDS formulation soft gels or tablets in Healthy, sponsored by Mayo Clinic.

Who is sponsoring NCT04551339?

NCT04551339 is sponsored by Mayo Clinic.

What condition does NCT04551339 study?

NCT04551339 studies Healthy, Health Care Worker Patient Transmission, Aging.

Is NCT04551339 still recruiting?

NCT04551339 is currently completed. Last updated 10 August 2021.

Last reviewed 2021-08-10 · How we verify

NCT04551339: ZnCOVID-19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19

Completed NA Last updated 10 August 2021

What this trial tests

NA trial testing PreserVision AREDS formulation soft gels or tablets in Healthy in 2,700 participants. Completed in 28 May 2021.

Timeline

28 September 2020

Primary endpoint
28 May 2021

28 May 2021

Quick facts

Lead sponsor	Mayo Clinic
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	2,700
Start date	28 September 2020
Primary completion	28 May 2021
Estimated completion	28 May 2021
Sites	3 locations across United States

Drugs / interventions tested

PreserVision AREDS formulation soft gels or tablets
Multivitamin with 11mg of zinc

Conditions studied

Healthy — all drugs for Healthy →
Health Care Worker Patient Transmission — all drugs for Health Care Worker Patient Transmission →
Aging — all drugs for Aging →

Sponsor

Mayo Clinic

Who can join

Adults 18 to 90, any sex, with Healthy or Health Care Worker Patient Transmission. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to look at high dose zinc versus multivitamin micronutrient supplementation to support immune health in the setting of the COVID-19 pandemic.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Micronutrients, Phytochemicals and Mediterranean Diet: A Potential Protective Role against COVID-19 through Modulation of PAF Actions and Metabolism.
Detopoulou P, Demopoulos CA, Antonopoulou S. · · 2021 · cited 52× · PMID 33573169 · DOI 10.3390/nu13020462
Zinc and selenium supplementation in COVID-19 prevention and treatment: a systematic review of the experimental studies.
Balboni E, Zagnoli F, Filippini T, Fairweather-Tait SJ, et al · · 2022 · cited 44× · PMID 35217499 · DOI 10.1016/j.jtemb.2022.126956
Potential molecular mechanisms of zinc- and copper-mediated antiviral activity on COVID-19.
Rani I, Goyal A, Bhatnagar M, Manhas S, et al · · 2021 · cited 43× · PMID 34284268 · DOI 10.1016/j.nutres.2021.05.008
Perspectives on nano-nutraceuticals to manage pre and post COVID-19 infections.
Dubey AK, Chaudhry SK, Singh HB, Gupta VK, et al · · 2022 · cited 20× · PMID 35186674 · DOI 10.1016/j.btre.2022.e00712
A secondary approach with conventional medicines and supplements to recuperate current COVID-19 status.
Chowdhury A, Sajid M, Jahan N, Adelusi TI, et al · · 2021 · cited 6× · PMID 34332377 · DOI 10.1016/j.biopha.2021.111956
New Insights into Potential Beneficial Effects of Bioactive Compounds of Bee Products in Boosting Immunity to Fight COVID-19 Pandemic: Focus on Zinc and Polyphenols.
Bakour M, Laaroussi H, Ousaaid D, El Ghouizi A, et al · · 2022 · cited 5× · PMID 35267917 · DOI 10.3390/nu14050942
Does Prophylactic Oral Zinc Reduce the Risk of Contracting COVID-19?
Adrean SD, Schmitt K, Ng C, Pirouz A, et al · · 2022 · cited 1× · PMID 36337789 · DOI 10.7759/cureus.30881

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04551339 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 10 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04551339.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing